- Production of Nifedipine is moving from Germany to Asturias.
- The Asturias plant also produces 100% of Bayer's Aspirin.
- The new production line is expected to be operational by the end of 2021.
- Key officials, including the Minister of Health, will attend the commissioning.
Production Shift to Asturias
Bayer has initiated the production of Nifedipine, a compound used to relieve angina and reduce arterial hypertension, at its plant in Langreo, Asturias, Spain. This production is being relocated from Germany to Asturias.
Existing Production Capabilities
The Langreo plant is already responsible for producing 100% of Bayer's Acetylsalicylic Acid (Aspirin) and other key products. Nifedipine, marketed under the brand name Adelat, will be the sixth active ingredient produced at this facility.
Regulatory Approval and Timeline
In February, the Environmental Affairs Commission granted Bayer permission to produce Nifedipine at the Langreo plant. Following this approval, the company projected that the new production line would be operational by the end of 2021.
Commissioning Event
The commissioning of the new production line will be attended by notable figures, including the Minister of Health, Consumer Affairs and Social Welfare, Carolina Darias. She will be joined by Bernardo Kanauhati, CEO of Bayer in Spain and Portugal, and Jorge Álvarez, director of the Llaner plant, along with representatives from the government of the Principality.
